Domača stranEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
Prejšnji trg. dan.
0,67 $
Dnevni razpon
0,66 $ - 0,70 $
Letni razpon
0,66 $ - 3,13 $
Tržna kapitalizacija
15,20 mio. USD
Povprečni obseg
99,75 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 4,13 mio. | −10,38 % |
Stroški poslovanja | 4,85 mio. | −10,01 % |
Čisti dohodek | −2,07 mio. | 38,42 % |
Čista dobičkovnost prihodkov | −50,18 | 31,30 % |
Earnings per share | — | — |
EBITDA | −2,23 mio. | 10,97 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 8,29 mio. | −16,55 % |
Skupna sredstva | 29,21 mio. | −6,33 % |
Skupne obveznosti | 14,34 mio. | −9,96 % |
Celoten lastniški kapital | 14,87 mio. | — |
Shares outstanding | 22,00 mio. | — |
Razmerje P/B | 0,99 | — |
Donosnost sredstev | −23,48 % | — |
Donosnost kapitala | −33,02 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −2,07 mio. | 38,42 % |
Denar iz dejavnosti | −2,28 mio. | 32,09 % |
Denar iz naložb | −8,00 tis. | 52,94 % |
Denar iz financiranja | 4,69 mio. | — |
Neto sprememba denarnih sredstev | 2,41 mio. | 171,42 % |
Prost denarni tok | −1,11 mio. | 57,80 % |
Vizitka
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
Generalni direktor
Datum ustanovitve
2005
Sedež organizacije
Spletno mesto
Zaposleni
70
